Blog

Aleix Prat: A Step Forward in Personalizing Treatment and Follow-Up After Surviving Breast Cancer

Aleix Prat/clinicbarcelona.org

Jan 13, 2025, 16:57

Aleix Prat: A Step Forward in Personalizing Treatment and Follow-Up After Surviving Breast Cancer

Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared on LinkedIn:

“A Step Forward in Personalizing Treatment and Follow-Up After Surviving Breast Cancer

We are thrilled to share the results of our latest research, which links the activity of specific immune system genes to long-term survival in individuals who have overcome breast cancer.

Our study, led by Reveal Genomics and the Campus Clínic Barcelona, in collaboration with international institutions and Omniscope, reveals that analyzing these genes not only predicts disease prognosis (as we already knew) but also provides key insights into the general state of the immune system and the longevity of patients who appear to have overcome cancer.

The results indicate that high activity of these genes in the early stages of cancer is associated with a significant reduction in the risk of mortality, ranging from 41% to 47% in the 10 years following diagnosis.

This breakthrough would not have been possible without the collective effort of multiple international teams and the use of pioneering tools such as the HER2DX and TNBCDX tests developed by REVEAL GENOMICS, S.L.. These tests analyze patients’ immunological profiles to guide treatment decisions.

Although this study focuses on breast cancer, we have also identified similar associations in other types of cancer, such as melanoma, opening doors to even broader applications.

More information in the press releases:

Reveal Genomics.
Hospital Clínic.
La Vanguardia.”

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

Authros: L. Angelats et al.

Aleix Prat

Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona. He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.